Burkholderia Cepacia Complex Pathogenicity in Cystic Fibrosis

The Burkholderia cepacia complex (Bcc) comprises a group of closely related Gram-negative bacteria that pose a serious threat to individuals with cystic fibrosis (CF). These organisms colonise the thickened, dehydrated mucus of the CF lung, forming resilient biofilms that resist host defences and antibiotic therapy. Key virulence strategies include production of lipopolysaccharide-rich outer membranes, secretion of siderophores to scavenge iron, and sophisticated quorum sensing networks that regulate motility, exopolysaccharide production and toxin release. Chronic Bcc infection accelerates pulmonary decline and may trigger cepacia syndrome, a rapid and often fatal systemic condition. The intrinsic resistance of Bcc species to multiple drug classes – driven by efflux pumps, β-lactamases and reduced outer-membrane permeability – further complicates treatment. Global surveillance underscores the emergence of transmissible clones and divergent lineages, emphasising the need for rapid diagnostics, novel therapeutics and tailored infection-control measures to improve clinical outcomes.

Research from Nature Portfolio

Recent studies have employed genome-wide functional screens to uncover weaknesses in the Bcc cell envelope. By generating a high-density transposon mutant library in a clinical Burkholderia cenocepacia isolate and exposing it to a panel of cell envelope-targeting antibiotics, investigators identified key genes governing peptidoglycan synthesis, undecaprenyl phosphate metabolism and β-lactamase activity. This work revealed that combining β-lactam antibiotics with β-lactamase inhibitors, notably ceftazidime/avibactam, can overcome resistance mechanisms and potentiate drugs such as aztreonam and meropenem. The study also characterised the uptake and activity of the siderophore-conjugated cephalosporin cefiderocol, pointing to new combination therapies that exploit iron-transport pathways to breach the protective barrier of the Bcc cell envelope.

Burkholderia Cepacia Complex Pathogenicity in Cystic Fibrosis publication trend

The graph below shows the total number of articles in burkholderia cepacia complex pathogenicity in cystic fibrosis across all publications each year (not limited to Nature Index journals).

Technical terms

Biofilm: A structured community of bacterial cells enclosed in a self-produced polymeric matrix adherent to a surface.

Lipopolysaccharide (LPS): A complex glycolipid in the outer membrane of Gram-negative bacteria that contributes to structural integrity and immune evasion.

Siderophore: A specialised molecule secreted by bacteria to chelate iron from the host environment for uptake and utilisation.

Quorum sensing: A cell-to-cell communication system in bacteria that regulates gene expression in response to population density via small signal molecules.

Transposon sequencing (Tn-seq): A technique combining random transposon mutagenesis with high-throughput sequencing to identify genes essential for survival under specific conditions.

β-lactamase inhibitor: A compound that blocks the activity of β-lactamase enzymes, restoring the efficacy of β-lactam antibiotics against resistant bacteria.

References

1. Profiling cell envelope-antibiotic interactions reveals vulnerabilities to β-lactams in a multidrug-resistant bacterium. Nature Communications (2023).
2. [68Ga]Ga-Ornibactin for Burkholderia cepacia complex Infection Imaging Using Positron Emission Tomography. Journal of Medicinal Chemistry (2023).
3. Unraveling Burkholderia cenocepacia H111 fitness determinants using two animal models. mSystems (2025).
4. Genomic features, antimicrobial susceptibility, and epidemiological insights into Burkholderia cenocepacia clonal complex 31 isolates from bloodstream infections in India. Frontiers in Cellular and Infection Microbiology (2023).